Cargando…

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

OBJECTIVE: Major depressive disorder (MDD) is projected to be a leading cause of disability globally by 2030. Only a minority of patients remit with antidepressants. If assay of polymorphisms influencing central nervous system (CNS) bioavailability could guide prescribers to more effectively dose pa...

Descripción completa

Detalles Bibliográficos
Autor principal:	Singh, Ajeet B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540033/ https://www.ncbi.nlm.nih.gov/pubmed/26243841 http://dx.doi.org/10.9758/cpn.2015.13.2.150

Ejemplares similares

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants
por: Kanders, Sofia H., et al.
Publicado: (2019)

Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
por: Kato, Masaki, et al.
Publicado: (2020)

Pharmacogenetics of antidepressant response: An update
por: Drago, Antonio, et al.
Publicado: (2009)

Pharmacogenetics to Personalize Dosing of Tricyclic Antidepressants in Major Depressive Disorder: A Randomized Clinical Trial (PITA study)
por: Ter Hark, S., et al.
Publicado: (2023)

Insights from pharmacogenetic studies of antidepressants
por: Mandelli, Laura
Publicado: (2010)

Optimization of Antidepressant use with Pharmacogenetic Strategies
por: Torrellas, Clara, et al.
Publicado: (2017)

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
por: Lee, Kyung Ho, et al.
Publicado: (2021)

Analyses of Pharmacokinetic, Pharmacogenetic and Psychometrics Correlates of Antidepressants Use during Pregnancy and the Post-Partum Period
por: Cafaro, R., et al.
Publicado: (2022)

Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts
por: Ward, Joey, et al.
Publicado: (2018)

The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
por: Radosavljevic, Milica, et al.
Publicado: (2023)

Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
por: Aoki, Yumi, et al.
Publicado: (2022)

Treatment strategies to improve and sustain remission in major depressive disorder
por: Madhukar H., Trivedi, et al.
Publicado: (2008)

Polygenic heterogeneity in antidepressant treatment and placebo response
por: Nøhr, Anne Krogh, et al.
Publicado: (2022)

Antidepressant-induced Remission of Gardner Diamond Syndrome
por: Sawant, Neena Sanjiv, et al.
Publicado: (2012)

Frontal White Matter Anisotropy and Antidepressant Remission in Late-Life Depression
por: Taylor, Warren D., et al.
Publicado: (2008)

Early Response to Antidepressant Medications in Adults With Major Depressive Disorder: A Naturalistic Study and Odds of Remission at 14 Weeks
por: Belanger, Heather G., et al.
Publicado: (2023)

Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report
por: Stäuble, Céline K., et al.
Publicado: (2021)

quality of remission in the major depressive disorder
por: Chebli, H., et al.
Publicado: (2023)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
por: Brunet, Mercè, et al.
Publicado: (2022)

Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants
por: Kang, Hee-Ju, et al.
Publicado: (2020)

Baseline patterns of resting functional connectivity within posterior default-mode intranetwork associated with remission to antidepressants in major depressive disorder
por: Ye, Yanxiang, et al.
Publicado: (2022)

The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
por: Barlati, Stefano, et al.
Publicado: (2023)

The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report
por: Harkness, Kate L., et al.
Publicado: (2023)

Polygenic interactions with environmental adversity in the aetiology of major depressive disorder
por: Mullins, N., et al.
Publicado: (2016)

Polygenic loading for major depression is associated with specific medical comorbidity
por: McCoy, T H, et al.
Publicado: (2017)

Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode
por: Pjevac, Milica, et al.
Publicado: (2023)

Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study
por: Singh, Ajeet Bhagat, et al.
Publicado: (2015)

Should antidepressants be used for major depressive disorder?
por: Jakobsen, Janus Christian, et al.
Publicado: (2020)

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)

Pharmacogenetic Polygenic Risk Score for Bronchodilator Response in Children and Adolescents with Asthma: Proof-of-Concept
por: Sordillo, Joanne E., et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
por: Ochi, Taichi, et al.
Publicado: (2021)

Clinical Phenotypes Characterization in Pharmacogenetics Testing Trials for Major Depressive Disorder Treatment
por: Minelli, A.
Publicado: (2022)

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
por: Groessl, Erik J., et al.
Publicado: (2018)

Brain Structural Effects of Antidepressant Treatment in Major Depression
por: Dusi, Nicola, et al.
Publicado: (2015)

The Roles of BDNF in the Pathophysiology of Major Depression and in Antidepressant Treatment
por: Lee, Bun-Hee, et al.
Publicado: (2010)

An electroencephalographic signature predicts antidepressant response in major depression
por: Wu, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pln7arrnf0898rt2498vnvvnc3